RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
This study has been terminated.
First Posted: May 8, 2003
Last Update Posted: December 9, 2005
Information provided by:
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
|Mitochondrial Diseases||Drug: RG2133 (2',3',5'-tri-O-acetyluridine)||Phase 1|
|Study Design:||Allocation: Non-Randomized
Primary Purpose: Treatment
|Official Title:||An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases|
Resource links provided by NLM:
Genetics Home Reference related topics: ataxia neuropathy spectrum childhood myocerebrohepatopathy spectrum deoxyguanosine kinase deficiency mitochondrial complex I deficiency mitochondrial complex V deficiency mitochondrial neurogastrointestinal encephalopathy disease myoclonic epilepsy myopathy sensory ataxiaU.S. FDA Resources
Further study details as provided by Repligen Corporation:
Contacts and Locations
No Contacts or Locations Provided